JP4854198B2 - 慢性リンパ性白血病の処置のためのナイトロジェンマスタードアナログとイマチニブの組み合わせ剤 - Google Patents
慢性リンパ性白血病の処置のためのナイトロジェンマスタードアナログとイマチニブの組み合わせ剤 Download PDFInfo
- Publication number
- JP4854198B2 JP4854198B2 JP2004551110A JP2004551110A JP4854198B2 JP 4854198 B2 JP4854198 B2 JP 4854198B2 JP 2004551110 A JP2004551110 A JP 2004551110A JP 2004551110 A JP2004551110 A JP 2004551110A JP 4854198 B2 JP4854198 B2 JP 4854198B2
- Authority
- JP
- Japan
- Prior art keywords
- combination
- compound
- treatment
- clb
- chlorambucil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 title claims abstract description 37
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 title claims abstract description 36
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 title claims abstract description 35
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 239000005517 L01XE01 - Imatinib Substances 0.000 title 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title 1
- 229960002411 imatinib Drugs 0.000 title 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims abstract description 67
- 229960004630 chlorambucil Drugs 0.000 claims abstract description 67
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 5
- 229960000875 trofosfamide Drugs 0.000 claims abstract description 5
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960001055 uracil mustard Drugs 0.000 claims abstract description 5
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims abstract description 4
- 229960001842 estramustine Drugs 0.000 claims abstract description 4
- SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960004961 mechlorethamine Drugs 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 14
- -1 Nabemubichin Chemical compound 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 6
- SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 claims description 2
- XCDXSSFOJZZGQC-UHFFFAOYSA-N Chlornaphazine Chemical compound C1=CC=CC2=CC(N(CCCl)CCCl)=CC=C21 XCDXSSFOJZZGQC-UHFFFAOYSA-N 0.000 abstract 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 abstract 1
- 229950008249 chlornaphazine Drugs 0.000 abstract 1
- 229960004694 prednimustine Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 62
- 230000000694 effects Effects 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 239000004480 active ingredient Substances 0.000 description 16
- 210000004698 lymphocyte Anatomy 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010008962 Chronic lymphocytic leukaemia refractory Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42548102P | 2002-11-12 | 2002-11-12 | |
| US60/425,481 | 2002-11-12 | ||
| PCT/IB2003/005454 WO2004043466A1 (en) | 2002-11-12 | 2003-11-10 | Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006508118A JP2006508118A (ja) | 2006-03-09 |
| JP2006508118A5 JP2006508118A5 (enExample) | 2006-12-28 |
| JP4854198B2 true JP4854198B2 (ja) | 2012-01-18 |
Family
ID=32312996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004551110A Expired - Fee Related JP4854198B2 (ja) | 2002-11-12 | 2003-11-10 | 慢性リンパ性白血病の処置のためのナイトロジェンマスタードアナログとイマチニブの組み合わせ剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20060122186A1 (enExample) |
| EP (1) | EP1578426B1 (enExample) |
| JP (1) | JP4854198B2 (enExample) |
| CN (1) | CN100475212C (enExample) |
| AT (1) | ATE468855T1 (enExample) |
| AU (1) | AU2003280191A1 (enExample) |
| BR (1) | BR0316126A (enExample) |
| CA (1) | CA2504665C (enExample) |
| DE (1) | DE60332762D1 (enExample) |
| ES (1) | ES2348140T3 (enExample) |
| WO (1) | WO2004043466A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100386115C (zh) * | 2004-10-14 | 2008-05-07 | 孔庆忠 | 一种抗癌药物组合物 |
| US7872050B2 (en) | 2005-03-14 | 2011-01-18 | Yaupon Therapeutics Inc. | Stabilized compositions of volatile alkylating agents and methods of using thereof |
| US8501818B2 (en) * | 2005-03-14 | 2013-08-06 | Ceptaris Therapeutics, Inc. | Stabilized compositions of alkylating agents and methods of using same |
| US20110039943A1 (en) * | 2005-03-14 | 2011-02-17 | Robert Alonso | Methods for treating skin disorders with topical nitrogen mustard compositions |
| WO2009082662A1 (en) | 2007-12-21 | 2009-07-02 | Novartis Ag | Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia |
| WO2009120493A2 (en) * | 2008-03-27 | 2009-10-01 | Yaupon Therapeutics, Inc | Stabilized compositions of alkylating agents and methods of using same |
| EP2425830A1 (en) * | 2010-09-03 | 2012-03-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synergistic drug combination for the treatment of cancer |
| AU2014251038A1 (en) | 2013-04-08 | 2015-11-26 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| CN105997981A (zh) * | 2016-06-13 | 2016-10-12 | 崔坤峰 | 苯丁酸氮芥的药物组合物及其抗抑郁的医药用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506257A (en) * | 1992-03-26 | 1996-04-09 | University Of British Columbia | Aminocyclohexylamides for antiarrhythmic and anaesthetic uses |
| CN1088777A (zh) * | 1992-12-18 | 1994-07-06 | 丛繁滋 | 用于癌病灶直接给药的化疗药物制剂的制备方法 |
| AU2003232115A1 (en) * | 2002-05-13 | 2003-11-11 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of graft failure |
-
2003
- 2003-11-10 JP JP2004551110A patent/JP4854198B2/ja not_active Expired - Fee Related
- 2003-11-10 US US10/534,573 patent/US20060122186A1/en not_active Abandoned
- 2003-11-10 CA CA2504665A patent/CA2504665C/en not_active Expired - Fee Related
- 2003-11-10 DE DE60332762T patent/DE60332762D1/de not_active Expired - Lifetime
- 2003-11-10 AT AT03772561T patent/ATE468855T1/de not_active IP Right Cessation
- 2003-11-10 BR BR0316126-9A patent/BR0316126A/pt not_active IP Right Cessation
- 2003-11-10 ES ES03772561T patent/ES2348140T3/es not_active Expired - Lifetime
- 2003-11-10 AU AU2003280191A patent/AU2003280191A1/en not_active Abandoned
- 2003-11-10 WO PCT/IB2003/005454 patent/WO2004043466A1/en not_active Ceased
- 2003-11-10 CN CNB2003801031558A patent/CN100475212C/zh not_active Expired - Fee Related
- 2003-11-10 EP EP03772561A patent/EP1578426B1/en not_active Expired - Lifetime
-
2009
- 2009-08-19 US US12/543,868 patent/US8492383B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2504665A1 (en) | 2004-05-27 |
| JP2006508118A (ja) | 2006-03-09 |
| ES2348140T3 (es) | 2010-11-30 |
| US20060122186A1 (en) | 2006-06-08 |
| WO2004043466A1 (en) | 2004-05-27 |
| ATE468855T1 (de) | 2010-06-15 |
| BR0316126A (pt) | 2005-09-27 |
| CA2504665C (en) | 2012-12-18 |
| AU2003280191A1 (en) | 2004-06-03 |
| CN100475212C (zh) | 2009-04-08 |
| CN1711090A (zh) | 2005-12-21 |
| EP1578426B1 (en) | 2010-05-26 |
| US20090312290A1 (en) | 2009-12-17 |
| US8492383B2 (en) | 2013-07-23 |
| EP1578426A1 (en) | 2005-09-28 |
| DE60332762D1 (de) | 2010-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8268837B2 (en) | Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia | |
| US8492383B2 (en) | Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia | |
| US20090298791A1 (en) | Combinations comprising epothilones and antimetabolites | |
| TW202302095A (zh) | 使用ｂｅｔ抑制劑治療骨髓纖維化 | |
| US20100008923A1 (en) | Organic Compounds | |
| US20150051236A1 (en) | Combinations Useful for the Treatment of Chronic Lymphocytic Leukemia | |
| JP2006508118A5 (enExample) | ||
| JP4429732B2 (ja) | 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤 | |
| Xu et al. | Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance | |
| EP1485090B1 (en) | Combinations comprising an epothilone derivative and an imidazotetrazinone | |
| AU2007200677B2 (en) | Combinations comprising epothilones and anti-metabolites | |
| ZA200405099B (en) | Combinations comprising epothilones and antimetabolites |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061108 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061108 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100608 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100908 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100915 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101008 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101014 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101018 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20101014 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101108 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101207 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110406 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110614 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110927 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111025 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141104 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |